News Ovarian cancer data restores faith in Corcept's relacorilant After Corcept's setback with relacorilant in Cushing syndrome last month, the company has bounced back with strong survival data in ovarian cancer.
News 11 high-impact drugs to look out for in 2026 Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.
News FDA declines to approve Corcept's rare disorder drug As the celebrations for the end of 2025 gathered pace, the FDA delivered a year-end blow to Corcept by turning down its new Cushing's drug.
News Corxel's raises $287m for obesity drug, and other financings Our latest biofinancing round-up sees big rounds for Corxel and Caldera, with Mendra, Think Bio, Exciva, Cytotheryx, and Infinitopes also raising cash
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.